Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2RL1 | P55085 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 2/20 | 0.39 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
| ▸ | Q9HBH1 | 1/20 | 0.39 | |
| ▸ | SSTR3 | P32745 | 1/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.38 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.37 |
| ▸ | TFPI | P10646 | 1/20 | 0.37 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.36 |
| ▸ | GRPR | P30550 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3958038 | 0.99 | F2RL1 (0.41) | F2RL1F2PSMB5F10PDF | |
| SCHEMBL28744046 | 0.99 | F2RL1 (0.41) | F2RL1F2PSMB5F10PDF | |
| Hydrochloric Acid SCHEMBL9751549 | 0.94 | SSTR3 (0.42) | F2PSMB5F10PDFSSTR3 | |
| SCHEMBL11509533 | 0.93 | TFPI (0.41) | F10PDFSSTR3TFPIPRTN3 | |
| Hydrochloric Acid SCHEMBL10944483 | 0.92 | SSTR3 (0.41) | F2PSMB5F10PDFSSTR3 | |
| SCHEMBL10961877 | 0.91 | SSTR3 (0.41) | F2PSMB5F10PDFSSTR3 | |
| SCHEMBL3174933 | 0.91 | RXFP1 (0.41) | F2RL1F2PSMB5PDFSSTR3 | |
| 4-Nitroaniline SCHEMBL28072814 | 0.91 | F2RL1 (0.40) | F2RL1F2KEAP1RXFP1TFPI | |
| SCHEMBL10960145 | 0.91 | PDF (0.44) | F2RL1F2PSMB5F10PDF | |
| SCHEMBL29595898 | 0.89 | F2RL1 (0.51) | F2RL1PRTN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0420332-B1 | Method for determining the endogenous thrombin potential of plasma and blood, and also a kit for use in said method | HEMKER HENDRIK COENRAAD (NL) | 1995-04-26 | — | — | EP | claimed |
| EP-0420332-A2 | Method for determining the endogenous thrombin potential of plasma and blood, and also a kit for use in said method | Hemker, Hendrik Coenraad (NL) | 1991-04-03 | — | — | EP | claimed |
| US-4160025-A | Method of producing a blood-coagulation-promoting preparation from human blood plasma | IMMUNO AKTIENGESELLSCHAFT FUR CHEMISCH-MEDIZINISCHE PRODUKTE (AT) | 1979-07-03 | — | — | US | claimed |
| US-20130261130-A1 | NEUROTRYPSIN INHIBITORS | NEUROTUNE AG (CH) | 2013-10-03 | — | — | US | disclosed |
| EP-2635559-A2 | NEUROTRYPSIN INHIBITORS | Neurotune AG (CH) | 2013-09-11 | — | — | EP | disclosed |
| US-8389261-B2 | Method of isolation and purification of trypsin from pronase protease and use thereof | BAXTER HEALTHCARE S.A. (CH) | 2013-03-05 | — | — | US | disclosed |
| WO-2012059442-A2 | NEUROTRYPSIN INHIBITORS | NEUROTUNE AG (CH) | 2012-05-10 | — | — | WO | disclosed |
| US-20120003691-A1 | METHOD OF ISOLATION AND PURIFICATION OF TRYPSIN FROM PRONASE PROTEASE AND USE THEREOF | BAXTER HEALTHCARE S.A. (CH) | 2012-01-05 | — | — | US | disclosed |
| EP-1456228-B1 | METHOD OF ISOLATION AND PURIFICATION OF TRYPSIN FROM PRONASE AND USE THEREOF | BAXTER HEALTHCARE SA (CH) | 2011-05-04 | — | — | EP | disclosed |
| EP-1589029-B1 | Pyrazinone protease inhibitors | ORTHO MCNEIL PHARM INC (US) | 2010-03-17 | — | — | EP | disclosed |
| US-7659380-B2 | Method of isolation and purification of trypsin from pronase protease and use thereof | BAXTER HEALTHCARE S.A. (CH) | 2010-02-09 | — | — | US | disclosed |
| WO-1997036580-A1 | AMIDINOHYDRAZONES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 1997-10-09 | — | — | WO | disclosed |
| EP-0627925-A4 | TRYPSIN INHIBITORS. | CORVAS INT INC (US) | 1997-07-30 | — | — | EP | disclosed |
| US-5534498-A | TREATMENT OF PANCREATITIS | CORVAS INTERNATIONAL, INC. (US) | 1996-07-09 | — | — | US | disclosed |
| EP-0420332-B1 | Method for determining the endogenous thrombin potential of plasma and blood, and also a kit for use in said method | HEMKER HENDRIK COENRAAD (NL) | 1995-04-26 | — | — | EP | disclosed |
| EP-0627925-A1 | TRYPSIN INHIBITORS | CORVAS INTERNATIONAL, INC. (US) | 1994-12-14 | — | — | EP | disclosed |
| WO-1993014779-A1 | TRYPSIN INHIBITORS | CORVAS INTERNATIONAL, INC. (US) | 1993-08-05 | — | — | WO | disclosed |
| US-5192689-A | METHOD FOR DETERMINING THE ENDOGENOUS THROMBIN POTENTIAL OF PLASMA AND BLOOD | HEMKER HENDRIK C (NL) | 1993-03-09 | — | — | US | disclosed |
| EP-0420332-A2 | Method for determining the endogenous thrombin potential of plasma and blood, and also a kit for use in said method | Hemker, Hendrik Coenraad (NL) | 1991-04-03 | — | — | EP | disclosed |
| US-4160025-A | Method of producing a blood-coagulation-promoting preparation from human blood plasma | IMMUNO AKTIENGESELLSCHAFT FUR CHEMISCH-MEDIZINISCHE PRODUKTE (AT) | 1979-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261130-A1 | NEUROTRYPSIN INHIBITORS | MTPN, CHRNA7, CHRNA10 | F2RL1 2774/4885F2 4771/4885PSMB5 938/4885 |
| US-20120003691-A1 | METHOD OF ISOLATION AND PURIFICATION OF TRYPSIN FROM PRONASE PROTEASE AND USE THEREOF | PRSS3, RNPEP, NPEPPS | F2RL1 255/4885F2 1298/4885PSMB5 852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.